TEIJIN


<u>Flash Report</u> – FY13 Financial Performance & FY14 Outlook –

Teijin Limited May 9, 2014


Outline of FY13 Results

(1) Consolidated Results Highlights

(¥ billion)



(¥ billion)



TEIJIN

Operating Results

(¥ billion)	FY12	FY13	Difference
Net sales	745.7	784.4	+38.7
Operating income	12.4	18.1	+5.7
Operating margin	1.7%	2.3%	+0.6%
Nonoperating items (net)	(2.6)	1.8	+4.4
Ordinary income	9.8	19.9	+10.1
Extraordinary items (net)	(31.9)	(5.4)	+26.5
Income (loss) before income taxes	(22.1)	14.5	+36.6
Income taxes	6.1	7.9	+1.8
Minority interests in income	0.9	(1.7)	-2.7
Net income (loss)	(29.1)	8.4	+37.5
EPS (¥)	(29.61)	8.50	+38.11

EBITDA *1	59.2	63.7	+4.5
CAPEX ^{*2}	36.3	30.2	-6.1
Depreciation & amortization	46.9	45.7	-1.2
R&D expenses	33.2	32.2	-1.0
FCF	26.4	(8.7)	-35.1

*1 EBITDA = Operating income + Depreciation & amortization

*2 CAPEX includes investments in intangible assets

- Net sales and operating income: Up, owing to
 - Recovery in operating income in the Advanced Fibers and Composites segment, which countered sagging results in the Electronics Materials and Performance Polymer Products segment
- > Ordinary income: Doubled, thanks to
 - Increase in equity in earnings of affiliates
- Net income: Significant improvement from net loss in fiscal 2012, with contributing factors including
 - Gain on sales of investment securities
 - Sharp decline in extraordinary loss items, including impairment loss

<

PL exchange rate			
		FY12	FY13
		Average	Average
	¥/US\$	83	100
	¥/€	107	134
	US\$/€	1.29	1.34

Nonoperating items

Extraordinary items

(¥ billion)	FY12	FY13	Difference	(¥ billion)	FY12	FY13	Difference
Interest income	0.5	0.5	-0.0	Gain on sales of noncurrent assets	1.4	0.2	-1.3
Dividends income	0.8	1.0	+0.1	Gain on sales of investment securities	0.0	8.3	+8.3
Equity in earnings of affiliates	0.6	4.2	+3.6	Gain on revision of retirement benefit plans	0.4	-	-0.4
Gain on valuation of derivatives	2.6	1.5	-1.1	Others	0.5	0.7	+0.2
Other	1.1	1.4	+0.3	Extraordinary income, total	2.4	9.1	+6.8
Nonoperating income, total	5.6	8.5	+2.9	Loss on sales and retirement of noncurrent assets	1.5	1.7	+0.2
Interest expenses	3.4	3.4	-0.0	Loss on valuation of investment securities	0.8	0.1	-0.7
Foreign exchange losses	0.6	0.3	-0.3	Impairment loss	29.4	8.8	-20.6
Contribution	1.0	1.0	+0.0	Business structure improvement expenses	0.1	2.4	+2.3
Others	3.2	2.0	-1.1	Others	2.5	1.6	-0.9
Nonoperating expenses, total	8.2	6.7	-1.4	Extraordinary loss, total	34.3	14.5	-19.7
Nonoperating items, total	(2.6)	1.8	+4.4	.4 Extraordinary items, total (31.9) (5.4) +			+26.5
Equity in earnings of affiliates: ¥4.2 billion Revision of tax effect accounting for European affiliates				Impairment loss: ¥8.8 billion Suspension of production on two lines at our resin and plastics processing facility in Singapore;			

and plastics processing facility in Singapore; integration of films production facilities; discontinuation of in-house production of paraxylene

Financial Position

(¥ billion)		Mar. 31, 2014	Difference	(Impact of foreign exchange rate)
Total assets	762.4	768.4	+6.0	+23.9
Shareholders' equity	271.3	281.7	+10.4	+9.5
Interest-bearing debt	270.8	281.5	+10.8	+10.9

♦ BS exchange rate

	Mar. 31, 2013	Mar. 31, 2014
¥/US\$	94	103
¥/€	121	142
US\$/€	1.28	1.38

D/E ratio	1.00	1.00	+0.00
Equity ratio	35.6%	36.7%	+1.1%

Cash Flows

(¥ billion)	Operating activities	Investing activities	FCF	Financing activities and adjustments	Cash & cash equivalents
FY13	38.6	(47.3)	(8.7)	(7.0)	(15.7)
FY12	64.3	(37.9)	26.4	(11.0)	15.4


2		1 A A A A A A A A A A A A A A A A A A A	141
\succ	Finan	cial do	osition:

- Increase in total assets, liabilities • and shareholders' equity, owing to yen depreciation
- Moderate improvement in equity • ratio

Cash flows: \geq

- Fiscal 2012: Insurance income • related to the severe flooding in Thailand in late 2011
- Fiscal 2013: Acquisition of stake in • Kyorin Holdings, Inc.

Analysis of Changes in Operating Results and Financial Position




TEIJIN


(2) Operating Results by Segment (Comparison with FY12)

	Sales				Operating income (loss)			
(¥ billion)	FY12	FY13	Difference	% Change	FY12	FY13	Difference	% Change
Advanced Fibers and Composites	111.2	123.6	+12.4	+11.1%	(4.7)	5.7	+10.4	_
Electronics Materials and Performance Polymer Products	175.5	179.4	+3.9	+2.2%	(1.9)	(7.2)	-5.3	_
Healthcare	138.3	138.4	+0.1	+0.1%	24.8	24.5	-0.3	-1.1%
Trading and Retail	237.2	254.2	+17.0	+7.2%	4.7	5.2	+0.5	+10.0%
Subtotal	662.2	695.6	+33.4	+5.0%	22.9	28.2	+5.3	+23.3%
Others	83.5	88.8	+5.3	+6.4%	4.2	1.7	-2.5	-58.9%
Elimination and Corporate	_	_	_	_	(14.8)	(11.9)	+2.9	_
Total	745.7	784.4	+38.7	+5.2%	12.4	18.1	+5.7	+46.3%


1 Advanced Fibers and Composites




2 Electronics Materials and Performance Polymer Products



3 <u>Healthcare</u>



(4) <u>Trading and Retail</u>



		(¥ billion)	FY12	FY13	Difference	Change			
e		Sales	237.2	254.2	+17.0	+7.2%			
2		Operating income	4.7	5.2	+0.5	+10.0%			
Q-3Q		Summary & Action	ons						
	 Fiber materials and apparel: Exports of textiles for use in fashion apparel and sportswear were robust to Europe and North America; we expanded sales by promoting the development of high-performance materials in collaboration with customers and enhanced our fabric supply capabilities in the ASEAN region Textiles and apparel: Our mainstay OEM business benefited from increased shipments, but struggled at the income level as yen depreciation pushed up costs 								
		 Sales of materials applications rose Demand related t Great East Japan conditions for int remained sluggis 	worldwide o reconstru Earthquake erior materi	ction in are wound do	as affected wn; market	-			

Net Sales and Operating Income (comparison with previous forecast)

		FY13 Previous Outlook*				Difference		
	(¥ billion)	1H	2H	Total	1H	2H	Total	Difference
	Advanced Fibers and Composites	58.4	71.6	130.0	58.4	65.2	123.6	-6.4
	Electronics Materials and Performance Polymer Products	91.3	88.7	180.0	91.3	88.1	179.4	-0.6
	Healthcare	64.8	80.2	145.0	64.8	73.6	138.4	-6.6
Sales	Trading and Retail	120.9	134.1	255.0	120.9	133.3	254.2	-0.8
0,	Subtotal	335.5	374.5	710.0	335.5	360.1	695.6	-14.4
	Others	46.3	43.7	90.0	46.3	42.5	88.8	-1.2
	Total	381.8	418.2	800.0	381.8	402.6	784.4	-15.6
	Advanced Fibers and Composites	2.4	3.1	5.5	2.4	3.4	5.7	+0.2
Op	Electronics Materials and Performance Polymer Products	(2.7)	(2.3)	(5.0)	(2.7)	(4.5)	(7.2)	-2.2
Operating	Healthcare	9.4	15.6	25.0	9.4	15.2	24.5	-0.5
	Trading and Retail	2.3	3.2	5.5	2.3	2.8	5.2	-0.3
income (loss)	Subtotal	11.4	19.6	31.0	11.4	16.8	28.2	-2.8
ıe (lo	Others	(0.3)	2.8	2.5	(0.3)	2.1	1.7	-0.8
ss)	Elimination and Corporate	(5.9)	(7.6)	(13.5)	(5.9)	(6.0)	(11.9)	+1.6
	Total	5.2	14.8	20.0	5.2	12.9	18.1	-1.9

*Announced on November 1, 2013

Outlook for FY14

(1) Assessment of the operating environment

Global economic conditions: Recovery in developed countries is expected to continue underpinning global economic conditions, countering the negative impact of flagging growth in emerging economies

GDP Growth Forecasts

Source: International Monetary Fund (April 2014)

(%)	2011	2012	2013	2014 Projections	2015 Projections
World average	3.9	3.2	3.0	3.6	3.9
Advanced economies	1.7	1.4	1.3	2.2	2.3
Emerging markets and developing economies	6.2	5.0	4.7	4.9	5.3

Trends in key industries:

Automobiles	 The U.S. market continues to expand, although growth is slowing; European markets also remain on a gentle upswing Key Asian markets and emerging economies, notably the PRC and the ASEAN region, are growing
Aircraft	 Airbus S.A.S. and The Boeing Company are benefiting from brisk orders, as a result of which production rates are rising Demand for aircraft from low-cost carriers and other airlines in emerging economies, particularly in Asia, also continues to flourish
Electronics	 The industry remains dependent on growth in the smartphone and tablet computer markets The markets for flat-screen televisions and PCs has matured The shortening of product life cycles continues to fuel a trend toward lower sales prices
Healthcare	 Policies continue to focus on reducing sales prices through the revision of drug reimbursement prices, accelerating genericization and providing support for the discovery of new drugs Healthcare policy is driving growth in the home healthcare and nursing care services markets

(2) Summary of Outlook for FY14

	FY13	FY14	Differ	rence
(¥ billion)	1115	Outlook	Amount	%
Net sales	784.4	780.0	-4.4	-0.6%
Operating income	18.1	25.0	+6.9	+38.3%
Operating margin	2.3%	3.2%	_	+0.9%
Ordinary income	19.9	22.5	+2.6	+13.1%
Net income	8.4	10.0	+1.6	+19.7%

 Dividends Declared for Fiscal 2013 and Forecast for Fiscal 2014

TEIJIN

(¥/share)	FY13	FY14	Difference
Interim	2.0	2.0	Ι
Year-end	2.0	2.0	-
Annual dividends	4.0	4.0	_

EBITDA *1	63.7	70.0	+6.3
CAPEX *2	30.2	37.0	+6.8
Depreciation & amortization	45.7	45.0	-0.7
R&D expenses	32.2	34.0	+1.8
FCF	(8.7)	(10.0)	-1.3

(¥ billion)	Mar. 31, 2014	Mar. 31, 2015	Difference
Total assets	768.4	800.0	+31.6
Interest-bearing debt	281.5	290.0	+8.5


*1 EBITDA = (Operating income + Depreciation & amortization) *2 CAPEX includes investments in intangible assets

Exchange rate and Crude Oil Price Forecast for FY14

JPY per USD : 100 JPY per EUR : 135 Dubai crude oil price : US\$105/barrel

2. Outlook for FY14

TEIJIN



2. Outlook for FY14

• Outlook by Segment

	y 3	F	Y13 Results	5	F	Difference		
	(¥ billion)	1H	2H	Total	1H	2H	Total	Difference
	Advanced Fibers and Composites	58.4	65.2	123.6	65.0	65.0	130.0	+6.4
	Electronics Materials and Performance Polymer Products	91.3	88.1	179.4	90.0	90.0	180.0	+0.6
	Healthcare	64.8	73.6	138.4	65.0	75.0	140.0	+1.6
Sales	Trading and Retail	120.9	133.3	254.2	125.0	140.0	265.0	+10.8
	Subtotal	335.5	360.1	695.6	345.0	370.0	715.0	+19.4
	Others	46.3	42.5	88.8	30.0	35.0	65.0	-23.8
	Total	381.8	402.6	784.4	375.0	405.0	780.0	-4.4
	Advanced Fibers and Composites	2.4	3.4	5.7	3.0	3.5	6.5	+0.8
9	Electronics Materials and Performance Polymer Products	(2.7)	(4.5)	(7.2)	(2.0)	(1.0)	(3.0)	+4.2
Operating	Healthcare	9.4	15.2	24.5	11.0	14.0	25.0	+0.5
	Trading and Retail	2.3	2.8	5.2	2.0	3.5	5.5	+0.3
lcom	Subtotal	11.4	16.8	28.2	14.0	20.0	34.0	+5.8
income (loss)	Others	(0.3)	2.1	1.7	0.0	3.0	3.0	+1.3
s)	Elimination and Corporate	(5.9)	(6.0)	(11.9)	(6.0)	(6.0)	(12.0)	-0.1
	Total	5.2	12.9	18.1	8.0	17.0	25.0	+6.9

(3) Strategic actions in key businesses


Segment/business		Efforts in core markets/products and services	Restructuring initiatives and cost-cutting measures
Advanced	High-Performance Fibers	 Boost sales for use in tires and rubber reinforcements Increase sales for use in ballistic protection products and protective clothing; build effective supply chains 	 Shrink production and head office fixed costs Complete second transfer of operations to Thailand (Polyester fibers)
Fibers and Composites	Carbon Fibers and Composites	 Focus efforts to expand business on highly profitable applications, such as aircraft, and on areas in which barriers to new market entrants are significant, including pressure vessels Accelerate development of thermoplastic CFRP for automotive applications 	 Improve efficiency of two-pronged production configuration (Japan and Europe)
Electronics Materials and Performance	Resin and Plastics Processing	 Expand high-performance compounds and processed products businesses; scale back businesses centered on commoditized products Foster markets in the PRC and the ASEAN region Broaden sales for use in automobiles, housing, infrastructure development and healthcare 	 Production in Singapore plant to be integrated on two lines (Production to be suspended on one more line in May 2014) Reorganize sales companies Bring processes currently contracted out back in house
Polymer Products	Films	 Offer low-priced films for use in LCDs Increase sales of release films for manufacturing processes 	 Integrate and enhance efficiency of domestic production facilities Increase production capacity and promote production of high-value-added items at facilities in Asia
Healthcare	Pharmaceuticals	 Concentrate business expansion initiatives on febuxostat (Ensure effective life cycle management) Strengthen drug discovery capabilities; hasten clinical development efforts 	 Reduce costs by narrowing focus of marketing efforts (Make use of web-based sales promotions, among others)
	Home healthcare	 Boost sales of CPAP ventilators and AutoSet CS (Expand into devices used in the treatment of circulatory disorders) 	Rebuild operating foundation in the United States

2. Outlook for FY14

TEIJIN

(4) Analysis of changes in operating income forecast

- > Ongoing business restructuring initiatives and decisive measures to reduce costs
- > Emphasis on the expansion of core strategic businesses (advanced fibers and composites, healthcare)
- Consideration given to the impact of drug price revisions and lower sales prices for products sold in Asian markets and emerging economies



(5) Financial Highlights

	FY10 Actual	FY11 Actual	FY12 Actual	FY13 Actual	FY14 Outlook
ROA *1	6.1%	4.5%	1.6%	2.4%	3.2%
ROE *2	9.1%	4.2%	-10.3%	3.0%	3.6%
Operating margin	6.0%	4.0%	1.7%	2.3%	3.2%
D/E ratio	0.94	0.89	1.00	1.00	1.0
Shareholders' equity ratio	37.3%	38.3%	35.6%	36.7%	35%
Earnings per share (¥)	25.6	12.2	(29.6)	8.5	10.2
Dividends per share (¥)	5.0	6.0	4.0	4.0	4.0
Total assets (¥ billion)	761.5	762.1	762.4	768.4	800.0
Interest-bearing debt (¥ billion)	267.4	261.0	270.8	281.5	290.0
EBITDA (¥ billion) ^{*3}	105.0	86.3	59.2	63.7	70.0

- *1 ROA= Operating income/Total assets
- *2 ROE= Net income/Shareholders' equity
- *3 EBITDA = Operating income + Depreciation & amortization

Strategic Directions Under Teijin's New Management Team

- 1. Vision and policies
- 2. Business restructuring initiatives
- 3. Growth strategies
- 4. Looking ahead


1. Vision and policies

Maintain current long-term vision and basic policies

Evolve toward a solutions-based business model

Target growth by balancing business restructuring initiatives and growth strategies

Further enforce the concept of concentration and selectivity (focus allocation of resources)



Macroeconomic trends in 2012–2013

The slowdown in emerging economies persisted; in developed economies, the pace of growth remained fragile

Main factors behind the flagging operating results in the Teijin Group's materials businesses

- Weakened cost competitiveness
- Overemphasis on certain applications, customers and regions
- Insufficient efforts to cultivate new applications/markets and develop new products
- Delay in shift toward solutions-based business model



Earnings capacity in our materials businesses has been hampered

Principal short- to medium-term challenges

Rebuild the earnings bases of existing businesses by implementing business restructuring initiatives and reducing costs

Basic policies

We will reassess current businesses using four basic criteria: market potential, technological superiority, profitability and suitability for our business model.


Based on this, we will take steps to optimize the scale, location and configuration of production in each business.

Specific approaches

- Shut down/integrate production and R&D facilities in Japan and overseas
- Seek out beneficial strategic alliances, OEM arrangements and M&A opportunities
- Optimize the location and scale of commoditized materials businesses and concentrate investment in growth businesses
- Increase the efficiency of support departments and promote ongoing Groupwide efforts to reduce costs

2. Business restructuring initiatives

Impact of efforts to bolster profitability (including measures to reduce costs in addition to business restructuring initiatives)



Overall objective

Evolve as a company that is capable of providing value that responds to the needs of customers and society at large


- Basic policies
 - Expand highly profitable businesses, notably high-performance materials, healthcare and IT
 - Draw on the collective capabilities of the Teijin Group to create a new business model that integrates core competencies
 - Specific approaches
 - Press ahead steadily with key projects currently in progress (e.g., thermoplastic CFRP, healthcare-related undertakings)
 - Draw on the collective capabilities of the Teijin Group to cultivate new businesses that integrate materials and healthcare and in some cases also incorporate IT services
 - Expand mid- and downstream businesses by promoting collaboration between our materials businesses and our Trading and Retail Businesses Group
 - Actively seek beneficial strategic alliances, OEM arrangements and M&A opportunities
 - Realign and strengthen R&D structure

3. Growth strategies

Business domains

= Value to society


Healthcare **High-performance materials** High-performance materials that help make Synergies between our pharmaceuticals and home healthcare businesses the items in which they are used smaller, lighter, stronger and more attractive Nationwide home healthcare services network Technologies that facilitate the production of composites combining multiple materials Safety and peace of mind, comfort **Reduced consumption of energy and** resources; safety and protection Enhanced quality of life for patients \Rightarrow against disasters; clean energy IT Business development focused equally on B to B and B to C services Solid customer base (several million private users) Increasingly sophisticated services; collection and timely use of information



3. Growth strategies

Realign and strengthen R&D structure

Reorganize our R&D configuration, Engineering Division and New Business Development Group (commenced in April 2014)



- Add depth to technologies for production/commercialization of composites and downstream products
- Advance facility technologies




- Shift from a materials-based to a solutions-based business model
- Cultivate new businesses that integrate materials and healthcare and in some cases also incorporate IT services

3. Growth strategies


Outlook for allocation of management resources

We continue to promote the focused allocation of management resources with the aim of expanding core strategic businesses (advanced fibers and composites and healthcare)

Capital investment




In addition to approximately ¥30 billion/year on maintenance and refurbishment, we have resolved to invest a total of ¥100–¥200 billion in growth businesses over the next three years



TEIJIN Human Chemistry, Human Solutions

4. Looking ahead

Outlook for profitability



TEIJIN Disclaimer Regarding Forward-Looking Statements and Business Risks

Disclaimer

Any statements in this document, other than those of historical fact, are forward-looking statements about the future performance of Teijin and its Group companies, which are based on management's assumptions and beliefs in light of information currently available, and involve risks and uncertainties. Actual results may differ materially from these forecasts.

Business Risks

The Teijin Group recognizes certain risks as having the potential to affect its operating results and/or financial position. As of the date of this document, these risks included, but were not limited to, the risks listed below.

(1) Market-related risk

The Teijin Group manufactures and sells products, the sales of which may be affected by market conditions, competition with other companies and price fluctuations arising thereof, as well as fluctuations in raw materials prices and fuel costs, and such market factors as fluctuations in foreign exchange and interest rates.

(2) Product quality risk

Teijin's healthcare businesses manufacture and sell products that may affect the lives of users. Accordingly, quality issues relating to such products have the potential to negatively affect, among others, the Group's operating results, financial position and public reputation.

(3) R&D-related risk in the pharmaceuticals business

R&D in the pharmaceuticals business is characterized by significant investments of funds and time. Pharmaceuticals discovery research has a high incidence of failure to discover promising drugs. There are also risks that plans to apply for regulatory approval may be abandoned or that approval may be rescinded.

(4) Risks related to overseas operations

The Teijin Group has operations overseas. These operations are vulnerable to the impact of fluctuations in foreign exchange rates, as well as enforcement of new or unexpected changes to existing laws, regulations or tax systems that exert an adverse impact on the Group; economic fluctuations; or social unrest triggered by acts of terror or war.

(5) Risks related to accidents and disasters

In the event of a major natural disaster or unforeseen accident that results in damage to the Teijin Group's production facilities or significantly impedes the Group's supply chain, such developments may have a negative impact on the Group's operating results and/or financial position.

This material is based on the consolidated results for FY13 announced at 11:30 A.M. on May 9, 2014 (local time in Japan). All product names in this document are registered trademarks.

Changes in Net Sales and Operating Income

			FY12				FY13				
	(¥ billion)	1Q	2Q	3Q	4Q	Annual Total	1Q	2Q	3Q	4Q	Annual Total
	Advanced Fibers and Composites	26.1	26.6	25.2	33.2	111.2	28.2	30.2	30.4	34.8	123.6
	Electronics Materials and Performance Polymer Products	43.7	44.7	43.0	44.1	175.5	44.3	47.0	44.9	43.2	179.4
	Healthcare	31.2	33.1	35.7	38.3	138.3	31.5	33.3	36.6	37.0	138.4
Sales	Trading and Retail	54.9	60.8	60.9	60.7	237.2	57.1	63.8	66.0	67.3	254.2
	Total	156.0	165.2	164.8	176.2	662.2	161.1	174.4	177.9	182.3	695.6
	Others	18.4	18.7	20.0	26.4	83.5	22.4	23.9	18.6	23.9	88.8
	Total	174.3	183.9	184.8	202.6	745.7	183.5	198.3	196.4	206.2	784.4
	Advanced Fibers and Composites	(0.3)	0.6	(2.0)	(3.0)	(4.7)	0.2	2.2	0.9	2.4	5.7
0	Electronics Materials and Performance Polymer Products	1.6	(0.1)	(0.4)	(3.0)	(1.9)	(0.2)	(2.4)	(1.8)	(2.7)	(7.2)
Operating	Healthcare	3.8	5.5	7.1	8.4	24.8	4.6	4.8	8.0	7.2	24.5
	Trading and Retail	0.7	1.4	1.5	1.0	4.7	0.6	1.8	1.1	1.7	5.2
income	Total	5.8	7.4	6.2	3.5	22.9	5.2	6.3	8.2	8.7	28.2
e (loss)	Others	0.4	0.2	0.8	2.9	4.2	(0.0)	(0.3)	(0.5)	2.6	1.7
ss)	Elimination and Corporate	(3.2)	(3.2)	(4.3)	(4.1)	(14.8)	(3.3)	(2.6)	(3.1)	(2.9)	(11.9)
	Total	3.0	4.4	2.8	2.2	12.4	1.8	3.4	4.5	8.4	18.1

TEIJIN

Consolidated Balance Sheets

	(¥ billion)	June 30, 2012	Sept. 30, 2012	Dec. 31, 2012	Mar. 31, 2013	June 30, 2013	Sept. 30, 2013	Dec. 31, 2013	Mar. 31, 2014
Total assets		739.7	731.8	780.0	762.4	783.8	766.8	791.0	768.4
	Current assets	352.1	350.7	373.4	372.3	372.5	366.2	385.6	364.9
	Fixed assets	387.7	381.0	406.6	390.1	411.4	400.6	405.4	403.5
То	tal liabilities and net assets	739.7	731.8	780.0	762.4	783.8	766.8	791.0	768.4
	Liabilities	440.2	433.0	465.4	470.3	488.9	471.3	489.3	468.3
	[Interest-bearing debt]	254.7	252.3	274.9	270.8	287.7	292.3	296.9	281.5
	Net assets	299.5	298.8	314.5	292.1	294.9	295.5	301.7	300.1

Note: For more information, see Teijin's Consolidated Financial Statements Summary (for the year ended March 31, 2014).


Consolidated Statements of Income

		FY	12		FY13				
(¥ billion)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	
Net Sales	174.3	183.9	184.8	202.6	183.5	198.3	196.4	206.2	
Cost of sales	127.5	135.7	138.2	153.8	137.9	151.3	148.2	152.7	
Gross profit	46.8	48.3	46.6	48.8	45.6	47.0	48.3	53.5	
SG & A	43.9	43.9	43.8	46.6	43.8	43.6	43.8	45.1	
Operating income	3.0	4.4	2.8	2.2	1.8	3.4	4.5	8.4	
Nonoperating items (net)	(0.8)	(1.7)	0.8	(0.9)	(0.3)	(0.8)	4.1	(1.2)	
(Balance of financial expenses)	(0.3)	(0.7)	(0.5)	(0.5)	(0.3)	(0.7)	(0.4)	(0.5)	
(Equity on gains and losses of unconsolidated subsidiaries and affiliates)	0.4	0.1	0.1	(0.0)	(0.1)	0.4	3.4	0.5	
Ordinary income	2.2	2.7	3.6	1.3	1.6	2.5	8.6	7.2	
Extraordinary items(net)	(2.5)	1.6	(0.8)	(30.3)	(0.3)	5.3	(6.6)	(3.8)	
Income (loss) before income taxes	(0.3)	4.3	2.8	(29.0)	1.3	7.8	2.0	3.4	
Income taxes	1.6	3.0	0.9	0.6	1.1	3.9	3.1	(0.1)	
Minority interest (net)	(0.2)	0.2	0.5	0.4	0.0	(0.4)	(1.6)	0.2	
Net income (loss)	(1.6)	1.0	1.5	(30.0)	0.2	4.3	0.4	3.3	


Note: For more information, see Teijin's Consolidated Financial Statements Summary (for the year ended March 31, 2014).

TEIJIN


(Supplementary Information)



TEIJIN



• CAPEX, Depreciation & Amortization, and R&D Expenses



Sales of Principal Pharmaceuticals

									[{] billion)		
		FY12				FY13					
Product	Target disease	1Q	2Q	3Q	4Q	Annual Total	1Q	2Q	3Q	4Q	Annual Total
Bonalon®*	Osteoporosis	3.3	4.0	4.3	4.2	15.9	3.2	3.7	4.1	3.2	14.2
Onealfa®	Osteoporosis	1.8	2.0	2.1	2.0	7.9	1.5	1.7	1.9	1.4	6.6
Osteoporosis total		5.1	6.0	6.5	6.2	23.8	4.7	5.4	6.0	4.7	20.8
Venilon [®]	Severe infection	2.4	2.4	2.7	2.5	9.9	2.2	2.3	2.9	2.0	9.4
Mucosolvan®	Expectorant	2.1	1.9	2.6	2.4	9.0	1.7	1.8	2.4	1.9	7.9
Feburic®	Hyperuricemia and gout	0.7	1.2	1.7	1.9	5.5	1.9	2.5	3.4	3.7	11.4
Laxoberon®	Laxative	1.0	1.0	1.1	1.0	4.0	0.8	0.9	1.0	0.8	3.6
Tricor®	Hyperlipidemia	0.4	0.4	0.5	0.5	1.8	0.4	0.4	0.5	0.4	1.7
Bonalfa [®]	Psoriasis	0.4	0.3	0.4	0.3	1.4	0.3	0.3	0.3	0.3	1.3
Alvesco®	Asthma	0.3	0.3	0.4	0.4	1.3	0.3	0.3	0.4	0.3	1.3
Synvisc®	Osteoarthritis pain in the knee	0.4	0.3	0.3	0.2	1.2	0.2	0.2	0.2	0.2	0.8
Spiropent®	Bronchodilator	0.2	0.2	0.2	0.2	0.9	0.2	0.2	0.2	0.2	0.8

* Bonalon® is the registered trademark of Merck Sharp & Dohme Corp., Whitehouse Station, NJ, U.S.A.

Development status by therapeutic area

Phase of Clinical Trials							
	Phase I	Phase II	Phase III	Filed	Approved/New Launch		
Bone and joint disease		ITM-058 KTP-001			GTH-42J [Bonalon [®]]		
Respiratory disease	PTR-36 ^{*1}			NA872ET *6 [<i>Mucosolvan</i> ®]			
Cardio-vascular and metabolic disease	TMG-123	ITM-014 ^{*2} [Somatuline [®]] (New indication for neuroendocrine tumor)	TMX-67TLS ^{*3} [Feburic [®]] (New indication for tumor lysis syndrome) TMX-67 [Feburic [®]] (PRC)		ITM-014 [Somatuline [®]]		
Other			GGS-ON, -MPA, -CIDP [Venilon [®]] (New indication for optic neuritis) (New indication for microscopic polyangiitis ^{*4}) (New indication for chronic inflammatory demyelinating polyneuropathy ^{*5})				
*1 Phase I clinical trials for PTR-36 began in June 2013. *2 Phase II clinical trials for ITM-014N (Somatuline®) for the treatment of neuroendocrine tumors, a new indication, began in October 2013							

*3 Phase III clinical trials for TMX-67TLS (*Feburic*[®]) for the treatment of tumor lysis syndrome, a new indication, began in October 2013.

*4 Clinical trials for GGS-MPA (Venilon®) for the treatment of microscopic polyangitis, a new indication, moved up to phase III in November 2013.

*5 Phase III clinical trials for GGS-CIDP (*Venilon*[®]) for the treatment of chronic inflammatory demyelinating polyneuropathy, a new indication, began in December 2013.

*6 Teijin filed for approval to manufacture and market new formulation of *Mucosolvan* (NA872ET) in Japan in February 2014.

(As of March 31, 2014)

TEIJIN

• Status of new products

(As of March 31, 2014)

Brand name (Generic name)	Target disease	Medical properties/characteristics	Dosage form	Remarks
<i>Bonalon[®]</i> Jelly 35 mg (alendronate sodium hydrate)	Osteoporosis	Oral jelly formulation of <i>Bonalon</i> (alendronate sodium hydrate), currently sold as an osteoporosis drug; intended as the world's first jelly-form osteoporosis treatment; offers promise as an alternative for osteoporosis patients who dislike taking pills because it is easy to swallow and moderately firm, so holds shape; also promising because it is easily managed by elderly individuals.	Oral jelly	Licensed in from Merck & Co., Inc. (USA) Commenced sales in Japan on March 12, 2013

Notes: *Bonalon*[®] is the registered trademark of Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.

Newly developed pharmaceutical candidates

[Filed]

(As of March 31, 2014)

Code No. (Generic name)	Target disease	Medical properties/characteristics	Dosage form	Remarks
NA872ET (ambroxol hydrochloride)	Expectorant	Small, sustained-release tablet-form version of <i>Mucosolvan</i> (ambroxol hydrochloride) that is smaller than <i>Mucosolvan</i> L Capsule and thus easier to take. This version is promising because it allows easier apportioning of single doses.	Oral	Licensed in from Boehringher Ingelheim GmbH (Germany) Filed in Japan in February 2014.

TEIJIN

TEIJIN

Supplementary Ir	nformation)
------------------	-------------

[Phase III]

Code No. (Generic name)	Target disease	Medical properties/characteristics	Dosage form	Remarks
GGS-ON (freeze-dried sulfonated human immunoglobulin)	Optic neuritis	The immunoregulatory mechanism of this drug inhibits inflammation of the optic nerve; also promising because of its ability to restore lost visual function.	Injection	Under joint development with Kaketsuken (New indication)
GGS-MPA (freeze-dried sulfonated human immunoglobulin)	Microscopic polyangiitis	This drug's anti-inflammatory and immunoregulatory actions mitigate autoimmune vasculitis; also promising as a treatment for mononeuritis multiplex, a neuropathic disorder that is not alleviated by standard therapies.	Injection	Under joint development with Kaketsuken (New indication)
GGS-CIDP (freeze-dried sulfonated human immunoglobulin)	Chronic inflammatory demyelinating polyneuropathy	The immunoregulatory action of this drug inhibits inflammation of the peripheral nerves; the drug thus offers promise as a treatment that will restore lost muscle strength.	Injection	Under joint development with Kaketsuken (New indication)
TMX-67TLS (febuxostat)	Tumor lysis syndrome	A highly potent drug that selectively inhibits xanthine oxidase. Offers promise as a once-daily treatment option that prevents hyperuricemia in patients with malignant tumors who have undergone chemotherapy.	Oral	Developed in-house (New indication)
TMX-67 (febuxostat)	Hyperuricemia and gout	Trials to facilitate the licensing out of febuxostat (tablet- form treatment for hyperuricemia and gout currently sold in Japan and elsewhere) for sale in the PRC. A highly potent drug that selectively inhibits xanthine oxidase and is also safe for patients with impaired renal function who may be unable to tolerate existing treatments. Offers promise as a new treatment option that will improve the quality of life of hyperuricemia and gout sufferers in the PRC.	Oral	Under joint development with Astellas Pharma China, Inc.

[Phase II]

Code No. (Generic name)	Target disease	Medical properties/characteristics	Dosage form	Remarks
ITM-014N (lanreotide acetate)	Neuroendocrine tumors	Promising for the treatment of neuroendocrine tumors; inhibits cell proliferation and improves associated symptoms by interacting with somatostatin receptors to induce apoptosis (direct mechanism) and by blocking the release of neurotrophic factors (indirect mechanism).	Injection	Licensed in from Ipsen Pharma SAS (France) (New indication)
ITM-058	Osteoporosis	Promising for the treatment of osteoporosis due to potency in promoting bone formation, resulting in a rapid increase in bone density and reduction in the risk of fracture. Superior to existing PTH derived drugs in its ability to increase bone density and its safety (minimal risk of hypercalcemia).	Injection	Licensed in from Ipsen Pharma SAS (France)
KTP-001	Treatment for lumbar disc herniation	For use in chemonucleolysis for herniated lumbar discs; because it is a recombinant human protease—identical in structure to matrix metalloprotease, which promotes the spontaneous regression of herniated discs—this drug minimizes the risk of allergic reaction and facilitates the selective treatment of affected discs, thus reducing damage to surrounding tissue and enhancing the viability of this procedure as a minimally invasive alternative to surgery and expanding the treatment options available to patients.	Injection	Engineered by Professor Hirotaka Haro and Dr. Hiromichi Komori; under joint development with Kaketsuken

[Phase I]

Code No. (Generic name)	Target disease	Medical properties/characteristics	Dosage form	Remarks
TMG-123	Type 2 diabetes	Uses a novel mechanism (activation of glucokinase (GK) expressed predominantly in the liver) to control blood glucose levels; holds promise for use by patients with impaired glucose homeostasis. Also expected to offer greater convenience (administered once daily, does not require adjustment of dose for patients with renal insufficiency and minimal risk of drug interaction).	Tablet	
PTR-36	Bronchial asthma	Uses a novel mechanism (CRTh2 receptor antagonism) to control symptoms of asthma, facilitating effective long-term management of the disease; offers promise for use alone, delivering therapeutic value comparable to that of steroids, for patients with mild asthma; also offers promise for use in tandem with steroid inhalants, delivering sufficient therapeutic value for patients with mild to severe asthma.	Tablet	Licensed in from Pulmagen Therapeutics (Asthma) Limited

TEIJIN

Human Chemistry, Human Solutions

Human Chemistry, Human Solutions

The promise of the Teijin brand is summed up in the resonant statement: "Human Chemistry, Human Solutions".

Our promise is to continue to develop chemical technologies that are friendly to both people and the global environment. It is to keep providing solutions that deliver the real value that society and our customers expect.

We will certainly keep this promise. Constantly working to enhance the Quality of Life -our very reason for being as a company- the Teijin Group will continue to win the trust of society and our customers.